Testing for Dihydropyrimidine Dehydrogenase Deficiency to Individualize 5-Fluorouracil Therapy

Area of Science:

• Pharmacogenetics
• Clinical Oncology
• Drug Metabolism

Background:

• Severe adverse events from 5-fluorouracil (5-FU) chemotherapy affect one in three patients, often leading to treatment discontinuation.
• Dihydropyrimidine dehydrogenase (DPD) deficiency, a pharmacogenetic syndrome, is a known risk factor for 5-FU toxicity.
• A significant number of patients with DPD deficiency experience life-threatening toxicity when treated with 5-FU.

Purpose of the Study:

• To review advancements in identifying actionable markers for DPD deficiency.
• To discuss the integration of DPD deficiency testing into clinical decision-making for 5-FU chemotherapy.
• To address limitations of current diagnostic tests and the regulatory landscape of pre-therapeutic DPYD testing.

Main Methods:

• Literature review of recent progress in DPD deficiency marker identification.
• Analysis of current clinical guidelines and regulatory status for DPYD testing.
• Discussion of challenges in implementing pre-therapeutic DPD deficiency screening.

Main Results:

• Progress has been made in identifying genetic markers associated with DPD deficiency.
• The integration of DPD deficiency testing into clinical practice is evolving.
• Current testing methods have limitations, and regulatory frameworks for pre-therapeutic DPYD testing are under development.

Conclusions:

• Actionable markers for DPD deficiency are increasingly available.
• Clinical implementation of DPYD testing is essential for mitigating 5-FU toxicity.
• Addressing limitations and regulatory aspects of DPD testing is critical for patient safety.